These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 9326415)

  • 1. Combination of decay-accelerating factor expression and alpha1,3-galactosyltransferase knockout affords added protection from human complement-mediated injury.
    van Denderen BJ; Salvaris E; Romanella M; Aminian A; Katerelos M; Tange MJ; Pearse MJ; d'Apice AJ
    Transplantation; 1997 Sep; 64(6):882-8. PubMed ID: 9326415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knock out of alpha1,3-galactosyltransferase or expression of alpha1,2-fucosyltransferase further protects CD55- and CD59-expressing mouse hearts in an ex vivo model of xenograft rejection.
    Cowan PJ; Chen CG; Shinkel TA; Fisicaro N; Salvaris E; Aminian A; Romanella M; Pearse MJ; d'Apice AJ
    Transplantation; 1998 Jun; 65(12):1599-604. PubMed ID: 9665076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic expression of human alpha1,2-fucosyltransferase (H-transferase) prolongs mouse heart survival in an ex vivo model of xenograft rejection.
    Chen CG; Salvaris EJ; Romanella M; Aminian A; Katerelos M; Fisicaro N; d'Apice AJ; Pearse MJ
    Transplantation; 1998 Mar; 65(6):832-7. PubMed ID: 9539096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies.
    Shimizu I; Smith NR; Zhao G; Medof E; Sykes M
    Transplantation; 2006 Jan; 81(1):95-100. PubMed ID: 16421483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts.
    McGregor CG; Ricci D; Miyagi N; Stalboerger PG; Du Z; Oehler EA; Tazelaar HD; Byrne GW
    Transplantation; 2012 Apr; 93(7):686-92. PubMed ID: 22391577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates.
    Charreau B; Ménoret S; Tesson L; Azimzadeh A; Audet M; Wolf P; Marquet R; Verbakel C; Ijzermans J; Cowan P; Pearse M; d'Apice A; Soulillou JP; Anegon I
    Mol Med; 1999 Sep; 5(9):617-30. PubMed ID: 10551903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
    Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
    Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice.
    Byrne GW; McCurry KR; Kagan D; Quinn C; Martin MJ; Platt JL; Logan JS
    Transplantation; 1995 Nov; 60(10):1149-56. PubMed ID: 7482724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperacute rejection of vascularized heart transplants in BALB/c Gal knockout mice.
    Gock H; Salvaris E; Murray-Segal L; Mottram P; Han W; Pearse MJ; Goodman DJ; Cowan PJ; d'Apice AJ
    Xenotransplantation; 2000 Nov; 7(4):237-46. PubMed ID: 11081758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of hDAF-transgenic porcine endothelial cells against activation by human complement: role of the membrane attack complex.
    Fecke W; Long J; Richards A; Harrison R
    Xenotransplantation; 2002 Mar; 9(2):97-105. PubMed ID: 11897002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.
    Kroshus TJ; Salerno CT; Yeh CG; Higgins PJ; Bolman RM; Dalmasso AP
    Transplantation; 2000 Jun; 69(11):2282-9. PubMed ID: 10868627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in cell surface glycosylation in alpha1,3-galactosyltransferase knockout and alpha1,2-fucosyltransferase transgenic mice.
    Shinkel TA; Chen CG; Salvaris E; Henion TR; Barlow H; Galili U; Pearse MJ; d'Apice AJ
    Transplantation; 1997 Jul; 64(2):197-204. PubMed ID: 9256173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
    Mason JC; Ahmed Z; Mankoff R; Lidington EA; Ahmad S; Bhatia V; Kinderlerer A; Randi AM; Haskard DO
    Circ Res; 2002 Oct; 91(8):696-703. PubMed ID: 12386146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level co-expression of complement regulators on vascular endothelium in transgenic mice: CD55 and CD59 provide greater protection from human complement-mediated injury than CD59 alone.
    Cowan PJ; Shinkel TA; Aminian A; Romanella M; Wigley PL; Lonie AJ; Nottle MB; Pearse MJ; d'Apice AJ
    Xenotransplantation; 1998 Aug; 5(3):184-90. PubMed ID: 9741456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Gal antibody-mediated skin graft rejection requires a threshold level of Gal expression.
    Murray-Segal L; Gock H; Cowan PJ; d'Apice AJ
    Xenotransplantation; 2008 Feb; 15(1):20-6. PubMed ID: 18333910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Gal antibody-mediated allograft rejection in alpha1,3-galactosyltransferase gene knockout mice: a model of delayed xenograft rejection.
    Pearse MJ; Witort E; Mottram P; Han W; Murray-Segal L; Romanella M; Salvaris E; Shinkel TA; Goodman DJ; d'Apice AJ
    Transplantation; 1998 Sep; 66(6):748-54. PubMed ID: 9771838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human decay-accelerating factor expressed on rat hearts inhibits leukocyte adhesion.
    Verbakel CA; van Duikeren S; de Bruin RW; Marquet RL; IJzermans JN
    Transpl Int; 2003 Mar; 16(3):168-72. PubMed ID: 12664211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack.
    van Denderen BJ; Pearse MJ; Katerelos M; Nottle MB; Du ZT; Aminian A; Adam WR; Shenoy-Scaria A; Lublin DM; Shinkel TA; d'Apice AJ
    Transplantation; 1996 Feb; 61(4):582-8. PubMed ID: 8610385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts.
    Schmoeckel M; Nollert G; Shahmohammadi M; Young VK; Chavez G; Kasper-König W; White DJ; Müller-Höcker J; Arendt RM; Wilbert-Lampen U; Hammer C; Reichart B
    Transplantation; 1996 Sep; 62(6):729-34. PubMed ID: 8824468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A desirable transgenic strategy using GGTA1 endogenous promoter-mediated knock-in for xenotransplantation model.
    Ko N; Shim J; Kim HJ; Lee Y; Park JK; Kwak K; Lee JW; Jin DI; Kim H; Choi K
    Sci Rep; 2022 Jun; 12(1):9611. PubMed ID: 35688851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.